Lineage Cell Therapeutics (LCTX) Goodwill & Intangibles (2010 - 2026)

Lineage Cell Therapeutics has reported Goodwill & Intangibles for 17 years, with the latest figure at $42.4 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles rose 297.04% year-over-year to $42.4 million; the trailing twelve-month figure through Mar 2026 stood at $42.4 million (up 297.04% YoY), and the FY2025 full-year result was $42.4 million, up 297.04% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $42.4 million, roughly flat from $42.4 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $76.8 million in Q4 2022, with the low at $10.7 million in Q4 2024.
• Historically, Goodwill & Intangibles has averaged $51.0 million across 5 years, with a median of $57.2 million in 2022.
• The largest YoY upside for Goodwill & Intangibles was 297.04% in 2025 against a maximum downside of 86.11% in 2025.
• Lineage Cell Therapeutics' Goodwill & Intangibles stood at $76.8 million in 2022, then dropped by 25.52% to $57.2 million in 2023, then tumbled by 81.35% to $10.7 million in 2024, then jumped by 297.04% to $42.4 million in 2025, then changed by 0.0% to $42.4 million in 2026.
• The last three Goodwill & Intangibles figures came in at $42.4 million (Q1 2026), $42.4 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.